About Transfer Factor Complex
Transfer factor products are concentrated fractions marketed as a distinct class from whole bovine colostrum, often combining colostrum-derived components with egg-yolk-derived material (e.g., 4Life OvoFactor). The original hypothesis (Lawrence 1949 first observation; characterized in Lawrence 1955 J Clin Invest PMID 13233344) that small dialyzable molecules transfer antigen-specific immunity has not been reproduced under modern immunological standards; active species remain incompletely defined, and fraction-superiority claims over whole colostrum lack independent RCT support. Regulatory history is contentious — FDA warning letters to 4Life Research (2004) and a joint FDA/FTC action against 4Life over H1N1 marketing (2009) cited unsupported disease claims. CONTRAINDICATIONS: dairy allergy; lactose intolerance; egg allergy (for OvoFactor-containing products); immunosuppressive therapy.
What Transfer Factor Complex supports
- May support cellular immune function — small older RCTs only; fraction-superiority over whole colostrum is unsupported
How much Transfer Factor Complex to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
100–600
mg
Commercial transfer-factor products label at 100–600 mg of concentrated colostrum and/or egg-yolk-derived fractions (e.g., 4Life UltraFactor XF / NanoFactor / OvoFactor blends). The dominant brand (4Life) standardizes Tri-Factor at ~300–600 mg. There is no RCT-derived therapeutic dose for the fraction class; manufacturer claims of per-mg superiority over whole colostrum are unsupported by independent studies.
Clinical evidence
Limited clinical evidence. Small older RCTs in specific infections (HSV, fungal) cited by manufacturers; no independent trials of transfer-factor fractions; FDA/FTC enforcement history for unsupported claims (4Life 2004, 2009)
Examine.com